News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Mologen AG (MOLGF.PK): General Meeting Votes In Favour Of All Proposed Resolutions And Elects New Supervisory Board Members


8/15/2014 12:04:21 PM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Berlin, August 15, 2014 – At the Annual General Meeting of MOLOGEN AG on August 13, 2014, the shareholders voted with a large majority in favour of the proposals of the Management and Supervisory Board in all agenda items. Essentially, it has been decided to create a new authorized capital and, again, an employee options programme including the creation of a corresponding new conditional capital. In addition, two new members of the Supervisory Board have been elected on a regular cycle. The majority of the General Meeting voted in favour of the two candidates that had been proposed by the Supervisory Board: Oliver Krautscheid and Stefan M. Manth, MD. The Supervisory Board elected unanimously Oliver Krautscheid as the new Chairman and Stefan M. Manth, MD, as his deputy.

In total, around 69 per cent of the total voting share capital of MOLOGEN AG was present at the Annual General Meeting.

Before the votes, the CEO Dr. Matthias Schroff and CFO Jörg Petraß explained to the attending shareholders in particular the latest promising advances of the main product candidate MGN1703. In addition, the achieved advancement of the whole clinical pipeline, the economic situation of MOLOGEN AG and the further strategic plans of the company were presented.

About MOLOGEN AG

MOLOGEN AG is a biotechnology company specialized in the research and clinical development of cancer immune therapies and DNA vaccines against infectious diseases.

The cancer immune therapy MGN1703 is the company’s lead product and best-in-class TLR-9 agonist. It is currently developed for first-line maintenance treatment of colorectal cancer (pivotal randomized trial) and lung cancer (randomized trial). Second clinical-stage product is MGN1601, a therapeutic vaccination for the treatment of renal cancer. A phase I/II clinical study has already been completed successfully.

With unique, patented technologies and innovative products, MOLOGEN is pioneering immune therapies. MOLOGEN AG is a publicly listed company, headquartered in Berlin. The shares (ISIN DE0006637200) are listed in the Prime Standard of the German Stock Exchange.

www.mologen.com

Memberships in associations:

Biotechnologieverbund Berlin-Brandenburg (bbb) e.V. | BIO Deutschland e.V. | DECHEMA - Society for chemical technology and biotechnology e.V. | German industrial association of biotechnology (DIB) | Association for the Promotion of Science and Humanities in Germany | Association of German biotechnology companies (VBU) | Association of researching manufacturers of pharmaceuticals e.V. (VFA) | Association of the chemical industry e.V. (VCI)

MIDGE®, dSLIM®, EnanDIM® and MOLOGEN® are registered trademarks of MOLOGEN AG.

MOLOGEN AG

Claudia Nickolaus
Head of Investor Relations
Tel: +49 - 30 - 84 17 88 - 86
Fax: +49 - 30 - 84 17 88 - 50
investor@mologen.com

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES